Search for an ETF or holding
THIOGENESIS THERAPEUTICS CORP (TTI.V) is a Canadian company in the healthcare sector, listed on TSXV. Market capitalization of 31 million CAD (micro-cap).
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.